logo
Plus   Neg
Share
Email

Genentech: Phase III IMspire150 Study Of Tecentriq Meets Primary Goal

Genentech, a member of Swiss drug maker Roche Group (RHHBY), announced Friday that the Phase III IMspire150 study of Tecentriq Plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma met its primary endpoint of progression-free survival.

The study showed adding Tecentriq (atezolizumab) to Cotellic (cobimetinib) and Zelboraf (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf.

The company noted that a significant and clinically meaningful improvement in PFS was demonstrated in the study. The safety profile observed in IMspire150 was consistent with the known safety profiles of the individual medicines.

The company will present the results from the study at an upcoming medical meeting and discuss with health authorities, including the U.S. Food and Drug Administration and European
Medicines Agency.

Genentech said it has an extensive clinical trial development program for Tecentriq, with more than 50 ongoing studies, including multiple Phase III studies across lung, kidney, skin, breast, colorectal, prostate, ovarian, bladder, blood, liver and head and neck cancers.

Studies are evaluating Tecentriq alone and in combination with other medicines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter of fiscal 2021 on Thursday, Conagra Brands, Inc. (CAG) provided only its adjusted earnings and organic net sales growth guidance for the second quarter of fiscal 2021. The company is still not initiating annual outlook, as is usual, as the impact... Playboy Enterprises, Inc. and Mountain Crest Acquisition Corp. (MCAC) announced Thursday the signing of a definitive merger agreement to return Playboy to the public markets. They also signed definitive purchase agreements with institutional and accredited investors for the purchase of $50 million of... Snack and beverage giant PepsiCo Inc. (PEP) on Thursday reported a 16 percent decline in net income for the third quarter, reflecting revenue growth on continued strength in its global snacks and food business and improvement in its global beverage business. Both core earnings per share and net revenues for the quarter beat analysts' estimates.
Follow RTT